Leon, Spain

Paco Romero

This inventor holds 1 USPTO granted patent. Top assignee: Instituto Biomar, S.a.. Active years: 2008.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Paco Romero. Retrieved from https://idiyas.com/inventor/paco-romero-6u4vwfd6

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 5(Granted Patents)


Company Filing History:


Years Active: 2008

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Paco Romero: Innovator in Cancer Treatment

Introduction

Paco Romero is a notable inventor based in Leon, Spain. He has made significant contributions to the field of cancer treatment through his innovative research and development of new compounds.

Latest Patents

Romero holds a patent for cytotoxic depsipeptides, which are compounds of general formula (I) wherein R, R, and R groups are each independently selected from NR, O, and S. These compounds are of use in the treatment of cancers, showcasing his commitment to advancing medical science.

Career Highlights

Paco Romero is associated with Instituto Biomar, S.A., where he continues to work on groundbreaking research. His dedication to innovation in the pharmaceutical field has positioned him as a key figure in cancer research.

Collaborations

Romero collaborates with talented coworkers, including Leyre Malet and Librada Maria Cañedo, who contribute to his research efforts and help drive forward the mission of their organization.

Conclusion

Paco Romero's work in developing cytotoxic depsipeptides represents a significant advancement in cancer treatment. His contributions to the field highlight the importance of innovation in addressing critical health challenges.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…